Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
12 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 14
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
APAC
🇸🇬 SingaporeSG-S01 · Health Sciences Authority · Evaluation routes for therapeutic product registrationOfficialfull/abridged/verification, priority, reference agenciescurrent frameworkLatest observed: 2026-03-13🇸🇬 SingaporeSG-S02 · Health Sciences Authority · Application screening and evaluation stagesOfficialdossier screening, 50-day target, evaluation outputcurrent TATLatest observed: 2026-05-05🇸🇬 SingaporeSG-S03 · Agency for Care Effectiveness · Methods and processOfficialHTA, VBP, company-led submissions, 2026/27 DAC deadlinescurrent process and calendarsLatest observed: 2026-06-08🇸🇬 SingaporeSG-S04 · Agency for Care Effectiveness · Types of funding for drugs and vaccines in SingaporeOfficialACE/DAC, SDL, MAF, CDL rolescurrent educational factsheetLatest observed: checked live🇸🇬 SingaporeSG-S05 · Agency for Care Effectiveness · Drug and Vaccine Evaluation Methods and Process Guide, Version 3.1Officialtopic selection, evaluation, VBP/RSA, DAC, implementation, monitoring/review, RDFVersion 3.1 Sep 2023Latest observed: linked by current 2026 page🇸🇬 SingaporeSG-S06 · Ministry of Health · List of subsidised drugsOfficialSDL/MAF entries and institution availability caveatlist as of 2026-06-01Latest observed: 2026-05-31🇸🇬 SingaporeSG-S07 · Ministry of Health · Cancer Drug ListOfficialindication-level CDL, subsidy status, MSHL/MSV limitslist/limits updated 2026-06-01Latest observed: 2026-05-31🇸🇬 SingaporeSG-S08 · Ministry of Health · SDL and MAF drug subsidy pagesOfficialsubsidy purpose, residency, means testing, eligibilitycurrent subsidy frameworkLatest observed: 2025-01-02 / 2024-10-26🇸🇬 SingaporeSG-S08 · Ministry of Health · SDL and MAF drug subsidy pagesOfficialsubsidy purpose, residency, means testing, eligibilitycurrent subsidy frameworkLatest observed: 2025-01-02 / 2024-10-26🇸🇬 SingaporeSG-S09 · ALPS Healthcare · Strategic procurement process guidelinesOfficialnational/cluster/PHI purchasing, mandatory supplier registration, PO-linked TRR and sole invoice channelSAP Business Network rollout effective 2026-08-03 / 2026-08-17 / 2027-01Latest observed: 2026-08-20🇸🇬 SingaporeSG-S10 · Health Sciences Authority · Variation applications and post-registration RMP obligationsOfficialpost-approval changes, RMP and utilisation requestscurrent frameworkLatest observed: 2026-03-17/19🇸🇬 SingaporeSG-S10 · Health Sciences Authority · Variation applications and post-registration RMP obligationsOfficialpost-approval changes, RMP and utilisation requestscurrent frameworkLatest observed: 2026-03-17/19🇸🇬 SingaporeSG-S11 · Ministry of Health · Medication Assistance Fund Plus and healthcare financing supportOfficialdiscretionary last-line support after insurance/MediSave2026-01-29Latest observed: 2026-01-29🇸🇬 SingaporeSG-S12 · Health Sciences Authority · How therapeutic products are regulated by HSAOfficialregistration boundary and post-market actions2026-04-09Latest observed: 2026-04-09For education only — not regulatory, pricing or legal advice.